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Introduction
Decreased hypothalamic–pituitary–adrenal activity, partic-
ularly a blunted response to activation of the immune
system, is strongly implicated in the onset and persistence
of inflammatory arthritis (IA) [1]. Dehydroepiandrosterone
(DHEA) and its sulfate ester (DHEAS) are the steroid
Abstract
Hypothalamic–pituitary–adrenal underactivity has been reported in rheumatoid arthritis (RA). This
phenomenon has implications with regard to the pathogenesis and treatment of the disease. The
present study was designed to evaluate the secretion of the adrenal androgen
dehydroepiandrosterone sulfate (DHEAS) and its relation to clinical variables in RA,
spondyloarthropathy (Spa), and undifferentiated inflammatory arthritis (UIA). Eighty-seven patients (38
with RA, 29 with Spa, and 20 with UIA) were studied, of whom 54 were women. Only 12 patients
(14%) had taken glucocorticoids previously. Age-matched, healthy women (134) and men (149)
served as controls. Fasting blood samples were taken for determination of the erythrocyte
sedimentation rate (ESR), serum DHEAS and insulin, and plasma glucose. Insulin resistance was
estimated by the homeostasis-model assessment (HOMAIR). DHEAS concentrations were significantly
decreased in both women and men with inflammatory arthritis (IA) (P < 0.001). In 24 patients (28%),
DHEAS levels were below the lower extreme ranges found for controls. Multiple intergroup
comparisons revealed similarly decreased concentrations in each disease subset in both women and
men. After the ESR, previous glucocorticoid usage, current treatment with nonsteroidal anti-
inflammatory drugs, duration of disease and HOMAIR were controlled for, the differences in DHEAS
levels between patients and controls were markedly attenuated in women (P = 0.050) and were no
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hormones most abundantly produced by the human
adrenal cortex, and therefore are probably of biological
importance [2,3]. Low serum concentrations of these
weak androgens more sensitively confirm hypothalamic–
pituitary–adrenal hypofunction than does glucocorticoid
secretion [4]. In young women with rheumatoid arthritis
(RA), decreased DHEA and DHEAS levels are signifi-
cantly correlated with low early-morning cortisol concen-
trations and high basal levels of interleukin-6 [5]. Both
glucocorticoids and testosterone, of which DHEA is a pre-
cursor, attenuate cytokine production by synovial inflam-
matory cells [1].
DHEAS concentrations before the onset of RA in pre-
menopausal women were reported to be reduced in two
studies by Masi et al [6,7] and normal in a study by Heikilla
et al [8], respectively. However, the findings in the latter
report may have been related to a variation in the use of lab-
oratory methods to assay DHEA levels or a genetically dif-
ferent type of RA in Finnish patients [6]. The concentration
of DHEAS in both serum and synovial tissue is decreased in
established RA [9]. The decrease is more pronounced in
patients taking glucocorticoids [10]. DHEA replacement in
the latter circumstance has been recommended as a means
of attenuating glucocorticoid-induced side effects [10].
Recently, the acute phase response and the severity of
disease were reported to correlate with decreased basal
DHEA levels in RA [5]. Treatment with nonsteroidal anti-
inflammatory drugs (NSAIDs) similarly attenuates hypothala-
mic–pituitary–adrenal axis function in RA [11]. Also, insulin
resistance, which may be a common disturbance in RA
[12], is associated with loss of the diurnal rhythm and
hyporesponsiveness of the hypothalamic–pituitary–adrenal
axis to stress [13].
In the present study, we compared serum DHEAS concen-
trations in 87 patients who had IA (RA, spondyloarthropathy
[Spa], or undifferentiated inflammatory arthritis [UIA]) with
the concentrations in controls matched for age and sex, and
investigated whether decreased serum DHEAS concentra-
tions in IA could be accounted for by the acute-phase
response, previous glucocorticoid usage, current NSAID
treatment, duration of disease, and insulin resistance.
Materials and methods
Patients, controls, and investigations
Eighty-seven consecutive nondiabetic patients were
enrolled. Their age (mean ± SD) was 49 ± 14 years (range
18–81). Eighty were Caucasian and 7 were Asian. Fifty-four
were women, of whom 26 had RA (FRA), 14 Spa (FSpa),
and 14 UIA (FUIA). Of the 33 men, 12 had RA (MRA), 15
Spa (MSpa), and 6 UIA (MUIA). The duration of disease
(mean ± SD) was 4.8 ± 7.8 years. Patients with RA met the
1987 criteria of the American Rheumatism Association for
the classification of RA [14] and patients with Spa met the
criteria of the European Spondyloarthropathy Study Group
(ESSG) for the classification of spondyloarthropathy [15].
Patients with UIA had swelling of at least two joint areas
for a minimum of 6 weeks without meeting the criteria for
either RA or Spa. Patients who had used glucocorticoids
within the previous 2 months or who were taking agents
known to affect insulin sensitivity or lipid metabolism were
excluded. Twenty-six patients were on no medication.
Agents taken were NSAIDs (n = 51), opioid agonists of
low efficacy (n = 7), paracetamol (n = 6), methotrexate
(n = 5), sulfasalazine (n = 4), misoprostol (n = 3), lanso-
prazole (n = 2), clonazepam (n = 2), mianserin (n = 2),
alendronate (n = 1), and amitryptiline (n = 1). Glucocorti-
coids had been taken by 12 patients (6 with FRA, 2 with
FUIA, 1 with MRA, 2 with MSpa, and 1 with MUIA).
The duration of disease was recorded and the body mass
index (kg/m2) determined in each patient. Fasting blood
samples were taken (between 0800 and 1000) for deter-
mination of the erythrocyte sedimentation rate (ESR),
serum DHEAS (chemiluminescent enzyme immunoassay;
Diagnostic Products Co, Los Angeles, CA, USA), lipids
and insulin (microparticle enzyme immunoassay on the
Axsym system; Abbott, IL, USA), and plasma glucose. The
intra-assay and interassay coefficients of variance were,
respectively, 1.9% and 1.2% for insulin, and 8.2% and
12.0% for DHEAS. Insulin resistance was estimated by
the homeostasis-model assessment (HOMAIR) [16] using
the formula fasting serum insulin (mU/ml) × fasting plasma
glucose (mmol/l)/22.5. Normal values for DHEAS were
obtained from 134 age-matched healthy women (mean
age 48 ± 17 years) and 149 age-matched healthy men
(mean age 52 ± 16 years).
Statistical analyses
Statistical analyses were made using the Statistical
Package for the Social Sciences (SPSS) program.
DHEAS concentrations were compared between patients
and controls using the one-way analysis of variance
(ANOVA). Multiple intergroup (FRA, FSpa, FUIA, MRA,
MSpa, MUIA) comparisons were done by the one-way
ANOVA and the Bonferroni post hoc test. The dependen-
cies of DHEAS levels on the ESR, previous glucocorticoid
usage, current NSAID treatment, duration of disease, and
HOMAIR were evaluated using simple linear regression
analyses and analyses of covariance. Results were
expressed as mean ± SD except in boxplots representing
DHEAS concentrations in the controls.
Results
DHEAS concentrations in patients and controls
The DHEAS concentrations in patients and controls are
reported in Table 1 and Figs 1 to 4. DHEAS concentra-
tions were significantly lower in both women and men with
IA than in their respective controls, and in 14 women
(26%) and 10 men (30%) with IA, these concentrations
fell below the extreme ranges (Figs 1 and 2) found in age-matched controls. The values found for the various
subsets of disease are given in Table 2. Multiple inter-
group comparisons of DHEAS concentrations revealed no
significant differences apart from higher levels in MSpa
than in MUIA (P = 0.04). Even in patients with MSpa,
DHEAS concentrations were lower than in male controls
(4.61 ± 1.87 vs 6.19 ± 4.12 mmol/l, P < 0.001). This dif-
ference remained equally significant after age was con-
trolled for.
The dependencies of DHEAS on clinical variables
The dependencies of DHEAS on clinical variables in
patients with IA are represented in Tables 3 and 4. None
of the evaluated variables contributed significantly to the
variance of DHEAS concentrations, except for NSAID
treatment in men with IA. After we had controlled for the
ESR, previous glucocorticoid usage, duration of disease,
current NSAID treatment, and HOMAIR, the differences in
DHEAS concentrations between patients and controls
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Figure 1
Serum DHEAS concentrations in female controls according to their age.
Figure 2
Serum DHEAS concentrations in male controls according to their age.
Figure 3
Serum DHEAS concentrations in female controls (unbroken line =
median; lower dotted line = 25th percentile; upper dotted line = 75th
percentile) and patients (dots = RA; triangles = Spa; squares = UIA).
Figure 4
Serum DHEAS concentrations in male controls. Symbols as in Fig. 3.were markedly attenuated in women (P = 0.050) and were
no longer present in men (P = 0.133).
Since the acute-phase response may not correlate with
disease activity in inflammatory arthritides other than RA
[17], a subgroup analysis was made in the 26 patients with
FRA (Table 5). In these, previous glucocorticoid usage pre-
dicted low DHEAS concentrations. However, even when
this variable was controlled for, DHEAS concentrations
remained lower in FRA than in female controls (P = 0.037).
Similarly, since DHEAS concentrations were higher in
MSpa than in MUIA, a subgroup analysis was made
(Table 6). In the MSpa patients, the HOMAIR and NSAID
treatment accounted for 15.2% and 16.7%, respectively,
of the variance in DHEAS concentrations. After the
respective variables were controlled for, DHEAS concen-
trations were no longer different between patients and
controls (P = 0.766). The body mass index was higher
(28.8 ± kg/m2) in the MSpa subgroup than in the other
groups of patients. The detailed results on the body mass
indices, lipids, and insulin resistance are the subject of a
separate report (submitted for publication).
Discussion
In the present study, we found decreased DHEAS con-
centrations in both women and men with RA, Spa, or UIA.
This finding was previously documented in RA [9]. With
regard to Spa, Hedman et al [18] reported normal DHEAS
concentrations in 25 patients who had psoriatic arthritis,
reactive arthritis, ankylosing spondylitis, or enteropathic
arthritis. Both elevated and decreased DHEAS concentra-
tions have been reported in ankylosing spondylitis [19,20].
In one of the latter reports, a significant correlation
between low DHEAS concentrations and a high acute-
phase response was found [20], as was recently reported
for RA [5]. The role of sex steroids in the pathogenesis of
Spa remains incompletely elucidated [19]. Of our 29
patients with Spa, 9 had ankylosing spondylitis, 7 psoriatic
arthritis, and 13 reactive or undifferentiated spondylo-
arthropathy. Although the DHEAS concentrations were
highest in our patients with MSpa, the respective concen-
trations were still significantly lower than in age- and
gender-matched controls.
The number of patients enrolled in our study allowed us to
control for disease-related factors, i.e. the acute-phase
response, previous glucocorticoid usage, NSAID treat-
ment, duration of disease, and insulin resistance. The
overall disease activity was low in our patients (mean
ESR = 26 mm/hour), which may explain why the investi-
gated disease-related parameters did not significantly
predict low DHEAS concentrations except for previous
glucocorticoid usage in RA women and NSAID treatments
in IA men. Even after disease-related factors were con-
trolled for, DHEAS concentrations tended to remain lower
Arthritis Research    Vol 3 No 3 Dessein et al
Table 1
Serum DHEAS concentrations (m mmol/l) in patients with IA and
in controls
Serum DHEAS (mmol/l)
Gender Controls Patients P
Women 3.65 ± 2.84 2.21 ± 2.06 < 0.001
Men 6.19 ± 4.12 3.66 ± 2.02 < 0.001
Values are shown as mean ± SD.
Table 2
Serum DHEAS concentrations (m mmol/l) in subsets of IA
IA subset DHEAS
FRA 2.01 ± 1.50
Fspa 3.04 ± 3.20
FUIA 1.74 ± 1.30
MRA 3.18 ± 2.07
Mspa 4.61 ± 1.87*
MUIA 2.23 ± 1.09
*vs MUIA: P = 0.04.
Table 3
Dependencies of DHEAS on disease-related variables in IA in
females
Variable aR2 P
ESR (mm/hour) 0.016 0.519
Duration of disease (months) 0.015 0.512
Glucocorticoid therapy 0.003 0.339
HOMAIR (mU.mmol/ml.l) 0.014 0.529
NSAID therapy 0.004 0.383
aR2, adjusted R2.
Table 4
Dependencies of DHEAS on disease-related variables in IA in
males
Variable aR2 P
ESR (mm/hour) 0.017 0.497
Duration of disease (months) 0.004 0.361
Glucocorticoid therapy 0.006 0.371
HOMAIR (mU.mmol/ml.l) 0.013 0.449
NSAID therapy 0.042 0.003
aR2, adjusted R2.in IA women than in their control subjects. This finding
indirectly supports the intriguing paradigm in which IA may
select for patients with subtle adrenal insufficiency, as pro-
posed by Masi et al [7]. Our finding of similarly decreased
concentrations in the various subsets of the disease sup-
ports the observation that risk factors for RA and inflam-
matory arthritides other than RA are alike [21]. In contrast,
DHEAS concentrations were no longer different in men
with IA from those in their controls after disease-related
parameters had been controlled for. Underactivity of the
hypothalamic–pituitary–gonadal axis, with decreased
testosterone production, was documented in men with RA
[22], and this underactivity may participate in the patho-
genesis in these patients [1]. The roles of hypoadrenalism
(decreased glucocorticoid as well as adrenal androgen
production) and hypogonadism in the onset and persis-
tence of disease in various IA subgroups and in both
genders deserves further investigation.
In 44 (51%) of our patients, serum DHEAS concentrations
were below the 25th percentile obtained in controls and in
24 patients (28%), these levels were below normal. Robin-
zon and Cutolo [10] recently attributed several side effects
of glucocorticoid therapy, including catabolism, muscular
atrophy, osteopenia, osteoporosis, and avascular necrosis,
to the suppressant effect of these agents on the hypothala-
mic–pituitary–adrenal axis, resulting in decreased DHEA
secretion. Also, low DHEAS concentrations constitute an
independent risk factor for cardiovascular disease [3] and
recently DHEA was shown to form an intergral part of low-
density lipoprotein and to protect the latter potently from
oxidation [23]. This is of interest in the present context,
since a 70% excess cardiovascular mortality was reported
in RA [24–26]. Indeed, IA and cardiovascular disease may
share a common predisposition [27].
DHEA replacement is associated with improvement of
physical and general wellbeing in elderly subjects [28]
and with lessening of disease activity in lupus [29] and of
osteoporosis in postmenopausal women [30]. It consti-
tutes part of the optimal treatment of frank adrenal insuffi-
ciency [31]. Robinzon and Cutolo suggested the use of
DHEA replacement, guided by monitoring of its concen-
tration in the blood, in RA patients taking glucocorticoids
[10]. Although short-term DHEA replacement therapy was
not associated with an improvement in disease activity in
11 patients with RA, the findings mentioned above
together with our results suggest that the indications for
DHEA replacement in IA should not be restricted to
patients on glucocorticoids. The role of DHEA supplemen-
tation in the treatment of IA requires further study.
Conclusion
In a controlled study on patients with IA, we found that
secretion of DHEAS is similarly reduced in RA, Spa, and
UIA. After we had controlled for the acute-phase
response, previous glucocorticoid usage, current NSAID
therapy, duration of disease, and insulin resistance, the dif-
ferences in DHEAS concentrations between patients and
controls matched for age and sex were attenuated in
women and were no longer present in men. The contribu-
tion of low DHEAS concentrations to the pathogenesis of
IA deserves further study. Also, in view of the impaired
health status associated with low DHEAS concentrations,
the role of DHEA replacement therapy in IA needs to be
investigated.
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